LUNG CANCER DIAGNOSTIC AND SCREENING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Lung cancer begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. Cancer from other organs also may spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. Lung cancers usually are grouped into two main types such as small cell and non-small cell. These types of lung cancer grow differently and are treated differently. According American Cancer Society non-small cell lung cancer is more common than small cell lung cancer. Different people have different symptoms for lung cancer. Some people have symptoms related to the lungs. Some people whose lung cancer has spread to other parts of the body (metastasized) have symptoms specific to that part of the body. Lung cancer symptoms may include coughing that gets worse or prolonged coughing, chest pain, shortness of breath, wheezing, coughing of blood, feeling very tired all the time, weight loss with no known cause.

According to the Centers for Disease Control and Prevention, lung cancer is the third most common cancer in the U.S. Most people in the U.S. die from lung cancer than any other type of cancer. For instance, According American Cancer Society, an estimated 154,050 Americans were expected to die from lung cancer in 2018, accounting for approximately 25% of all cancer deaths. Doctors may perform several tests to confirm lung cancer such as biomarker test, imaging test, and biopsy.

Market Dynamics

Regulatory approvals and launches of new screening test are expected to propel growth of the global lung cancer diagnostic and screening market during the forecast period. For instance, in August 2020, the U.S. Food and Drug Administration approved the liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

However, high cost of lung cancer screening test is also expected to limit the market growth. For instance, according to the American Board of International medicine a CT scan costs US$ 300 and more. These test one need to take periodically.

Key features of the study:

• This report provides in-depth analysis of the global lung cancer diagnostic and screening market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026-2033, considering 2024 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global lung cancer diagnostic and screening market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Abbott, Illumina, Inc, Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated,  NeoGenomics, NanoString, Myriad Genetics, Inc. F. Hoffmann-La Roche Ltd., Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global lung cancer diagnostic and screening market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for lung cancer diagnostic and screening market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

• Global Lung Cancer Diagnostic and Screening market, By Test Type:
• • Biomarkers Tests
    • EGFR Mutation Test
    • KRAS Mutation Test
    • ALK Test
    • HER2 Test
    • Others
  • Imaging Tests
    • Computed Tomography (CT) Scan
    • Positron Emission Tomography (PET) Scan
    • Chest X-RAY
    • Others
  • Biopsy
    • Needle Biopsy
    • Bronchoscopy Biopsy
    • Open Biopsy
    • Others

• Global Lung Cancer Diagnostic and Screening Market, By Cancer Type:
  • Non-small cell lung cancer
  • Small Cell Lung Cancer
• Global Lung Cancer Diagnostic and Screening Market, By End User:
  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
• Global Lung Cancer Diagnostic and Screening Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
    • By Test Type:
      • Biomarkers Tests
        • EGFR Mutation Test
        • KRAS Mutation Test
        • ALK Test
        • HER2 Test
        • Others
      • Imaging Tests
        • Computed Tomography (CT) Scan
        • Positron Emission Tomography (PET) Scan
        • Chest X-RAY
        • Others
      • Biopsy
        • Needle Biopsy
        • Bronchoscopy Biopsy
        • Open Biopsy
        • Others
    • By Cancer Type:
      • Non-small cell lung cancer
      • Small Cell Lung Cancer
    • By End User:
      • Hospitals
      • Independent Diagnostic Laboratories
      • Diagnostic Imaging Centers
      • Cancer Research Institutes
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
    • By Test Type:
      • Biomarkers Tests
        • EGFR Mutation Test
        • KRAS Mutation Test
        • ALK Test
        • HER2 Test
        • Others
      • Imaging Tests
        • Computed Tomography (CT) Scan
        • Positron Emission Tomography (PET) Scan
        • Chest X-RAY
        • Others
      • Biopsy
        • Needle Biopsy
        • Bronchoscopy Biopsy
        • Open Biopsy
        • Others
    • By Cancer Type:
      • Non-small cell lung cancer
      • Small Cell Lung Cancer
    • By End User:
      • Hospitals
      • Independent Diagnostic Laboratories
      • Diagnostic Imaging Centers
      • Cancer Research Institutes
  • Asia Pacific
    • By Country:
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
    • By Test Type:
      • Biomarkers Tests
        • EGFR Mutation Test
        • KRAS Mutation Test
        • ALK Test
        • HER2 Test
        • Others
      • Imaging Tests
        • Computed Tomography (CT) Scan
        • Positron Emission Tomography (PET) Scan
        • Chest X-RAY
        • Others
      • Biopsy
        • Needle Biopsy
        • Bronchoscopy Biopsy
        • Open Biopsy
        • Others
    • By Cancer Type:
      • Non-small cell lung cancer
      • Small Cell Lung Cancer
    • By End User:
      • Hospitals
      • Independent Diagnostic Laboratories
      • Diagnostic Imaging Centers
      • Cancer Research Institutes
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • By Test Type:
      • Biomarkers Tests
        • EGFR Mutation Test
        • KRAS Mutation Test
        • ALK Test
        • HER2 Test
        • Others
      • Imaging Tests
        • Computed Tomography (CT) Scan
        • Positron Emission Tomography (PET) Scan
        • Chest X-RAY
        • Others
      • Biopsy
        • Needle Biopsy
        • Bronchoscopy Biopsy
        • Open Biopsy
        • Others
    • By Cancer Type:
      • Non-small cell lung cancer
      • Small Cell Lung Cancer
    • By End User:
      • Hospitals
      • Independent Diagnostic Laboratories
      • Diagnostic Imaging Centers
      • Cancer Research Institutes
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • By Test Type:
      • Biomarkers Tests
        • EGFR Mutation Test
        • KRAS Mutation Test
        • ALK Test
        • HER2 Test
        • Others
      • Imaging Tests
        • Computed Tomography (CT) Scan
        • Positron Emission Tomography (PET) Scan
        • Chest X-RAY
        • Others
      • Biopsy
        • Needle Biopsy
        • Bronchoscopy Biopsy
        • Open Biopsy
        • Others
    • By Cancer Type:
      • Non-small cell lung cancer
      • Small Cell Lung Cancer
    • By End User:
      • Hospitals
      • Independent Diagnostic Laboratories
      • Diagnostic Imaging Centers
      • Cancer Research Institutes
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
    • By Test Type:
      • Biomarkers Tests
        • EGFR Mutation Test
        • KRAS Mutation Test
        • ALK Test
        • HER2 Test
        • Others
      • Imaging Tests
        • Computed Tomography (CT) Scan
        • Positron Emission Tomography (PET) Scan
        • Chest X-RAY
        • Others
      • Biopsy
        • Needle Biopsy
        • Bronchoscopy Biopsy
        • Open Biopsy
        • Others
    • By Cancer Type:
      • Non-small cell lung cancer
      • Small Cell Lung Cancer
    • By End User:
      • Hospitals
      • Independent Diagnostic Laboratories
      • Diagnostic Imaging Centers
      • Cancer Research Institutes
• Company Profiles
  • Abbott
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Illumina, Inc
  • Thermo Fischer Scientific
  • QIAGEN
  • Quest Diagnostics Incorporated
  • NeoGenomics
  • NanoString
  • Myriad Genetics, Inc.
  • Hoffmann-La Roche Ltd
  • Danaher
  • Agilent Technologies, Inc.
  • AstraZeneca
  • Sanofi
  • Janssen Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.